Citicoline для Attention & Focus Difficulties

B Доказательства По меньшей мере одно рандомизированное исследование подтверждает это, с в целом согласованными результатами.

Researchers reviewing 14 studies found established evidence for improvements in attention, processing speed, and working memory with citicoline supplementation, particularly in elderly populations with existing cognitive complaints.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dciticoline\u0026condition\u003Dattention\u002Dfocus'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Итог

Key Study Findings

Randomized Controlled Trial Double-blind

Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study.

Dose: None или: placebo Outcome: ADHD symptom improvement Эффект: None None

Популяция: pediatric patients aged 7-12 years diagnosed with ADHD

Other 12 weeks

Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome.

Dose: 19.17% или: None Outcome: cognitive function Эффект: None None

Популяция: Covid-19 during the pandemic period between 2020 and 2022

Systematic Review n=8137

Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review.

Dose: None или: None Outcome: Cocaine craving reduction Эффект: None None

Популяция: Cocaine use disorder patients

Review

Cholinergic nervous system and glaucoma: From basic science to clinical applications.

Dose: None или: None Outcome: Mortality Эффект: None None

Популяция: None

Review

[X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion].

Dose: None или: None Outcome: None Эффект: None None

Популяция: None

Key Statistics

Исследования

1600

Участники

↑

Positive

Оценка

Referenced Papers

Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study. RCT

Clinical neuropharmacology None 2 цитирований

Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome. Other

Diagnostics (Basel, Switzerland) 2023

Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. Review

Brain sciences 2022 17 цитирований

Cholinergic nervous system and glaucoma: From basic science to clinical applications. Review

Progress in retinal … 2019 107 цитирований

[X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion]. Review

Revista de neurologia 2012 12 цитирований

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Часто используемые дозировки

general:: 250-500 mg/day
cognitivesupport:: 500-2,000 mg/day

Верхний предел: Well-tolerated up to 4,000 mg/day in clinical trials

Дозировки, изученные в исследованиях

Дозировка	Длительность	Эффект	N
None	--	Neutral	--
19.17%	12 weeks	Positive	--
None	--	Mixed	8137
None	--	Positive	--
None	--	Mixed	--

Лучшее время приёма: Morning or split dose; can be taken with or without food

Safety & Side Effects

Зарегистрированные побочные эффекты

⚠ Headache
⚠ Insomnia (if taken late in the day)
⚠ Mild gastrointestinal discomfort
⚠ Rare: restlessness or overstimulation

Известные взаимодействия

● Levodopa (may enhance dopaminergic effects)
● Cholinergic drugs (additive acetylcholine increase)
● Anticholinergics (may reduce citicoline effectiveness)

Допустимый верхний уровень потребления: Well-tolerated up to 4,000 mg/day in clinical trials

Всегда консультируйтесь с врачом перед началом приёма любых добавок.Всегда консультируйтесь с лечащим врачом перед началом приёма любой добавки.

Frequently Asked Questions

Does Citicoline help with Attention & Focus Difficulties?

Based on 14 studies with 1,600 participants, there is moderate evidence from clinical studies that Citicoline may support Attention & Focus Difficulties management. Our evidence grade is B (Good Evidence).

How much Citicoline should I take for Attention & Focus Difficulties?

Studies have used various dosages. A commonly studied range is 250-500 mg/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Citicoline?

Reported side effects may include Headache, Insomnia (if taken late in the day), Mild gastrointestinal discomfort, Rare: restlessness or overstimulation. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Citicoline and Attention & Focus Difficulties?

We rate the evidence as Grade B (Good Evidence). This rating is based on 14 peer-reviewed studies with 1,600 total participants. The overall direction of effect is positive.

Другие ингредиенты для Attention & Focus Difficulties

L-Theanine B Omega-3 Fatty Acids (DHA/EPA) C Bacopa monnieri C Phosphatidylserine C

Citicoline для других состояний

Memory Loss B

Краткий вывод

Evidence Strength72%

High confidence

Разбор исследований

RCT (1)Meta (0)Other (13)

Сравнить альтернативы

Узнайте, как другие ингредиенты сравниваются при данном состоянии.

Посмотреть все ингредиенты для Attention & Focus Difficulties

Узнать больше

References

[1] Isabel Barros Hübner et al.. Clin Neuropharmacol. Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study. doi:10.1097/WNF.0000000000000602 PubMed
[2] Milena Dimitrova et al.. Diagnostics (Basel). 2023. Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome. doi:10.3390/diagnostics13162703 PubMed
[3] Dângela Layne Silva Lassi et al.. Brain Sci. 2022. Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. doi:10.3390/brainsci12111546 PubMed
[4] Muneeb A Faiq et al.. Prog Retin Eye Res. 2019. Cholinergic nervous system and glaucoma: From basic science to clinical applications. doi:10.1016/j.preteyeres.2019.06.003 PubMed
[5] M Carmen Carrascosa-Romero et al.. Rev Neurol. 2012. [X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion]. PubMed

Отказ от ответственности FDA: Данные утверждения не были оценены Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов (FDA). Продукты и информация на этом сайте не предназначены для диагностики, лечения, излечения или профилактики каких-либо заболеваний. Представленные оценки доказательности основаны на нашем анализе опубликованных рецензируемых исследований и не являются медицинской консультацией. Всегда консультируйтесь с лечащим врачом перед началом приёма любых добавок.